Yanli Liu

发表

Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy

Akshay Jain, Guangfu Li, K. Cheng, 2022, Frontiers in Immunology.

Discovery of Small Anti‐ACE2 Peptides to Inhibit SARS‐CoV‐2 Infectivity

J. Qiu, E. Omoscharka, K. Cheng, 2021, Advanced therapeutics.

Solute carrier protein family may involve in radiation-induced radioresistance of non-small cell lung cancer

Xianrang Song, Jinming Yu, W. Guo, 2011, Journal of Cancer Research and Clinical Oncology.

Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer

Guangfu Li, K. Cheng, Zhen Zhao, 2021, Theranostics.

Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy

Akshay Jain, K. Cheng, Zhen Zhao, 2019, Journal of Immunotherapy for Cancer.

Aberrant ROS Served as an Acquired Vulnerability of Cisplatin-Resistant Lung Cancer

Ran Zhang, Jupeng Yuan, Fei Wang, 2021, Oxidative medicine and cellular longevity.

Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy.

Guangfu Li, Pratikkumar A. Patel, K. Cheng, 2022, Journal of medicinal chemistry.

Peptide-Based siRNA Nanocomplexes Targeting Hepatic Stellate Cells

K. Cheng, Yanli Liu, Umar-Farouk Mamani, 2023, Biomolecules.

Establishment of a Rat Model of Alcoholic Liver Fibrosis with Simulated Human Drinking Patterns and Low-Dose Chemical Stimulation

E. Omoscharka, K. Cheng, Yanli Liu, 2023, Biomolecules.